John Schiller, who along with Douglas Lowy received the 2017 Lasker~DeBakey Clinical Medical Research Award, provides an overview of HPV virus and infection, compares the three FDA approved vaccines against HPV, and explains the endpoints used in the clinical trials to prove vaccine efficacy. Schiller also discusses the high efficacy of HPV vaccine, which is exceptionally good at producing neutralizing antibodies and also benefits from the low mutation rate of HPV.

Visit iBiology to view seminars, stories, and find advice on science careers. iBiology was founded in 2006 by Lasker laureate Ron Vale.

Part One: HPV vaccines to prevent cancer

Why do HPV virus-like particle vaccines work so well?